Genetically Engineered Mesenchymal Stem Cells as a Nitric Oxide Reservoir for Acute Kidney Injury Therapy

Human MSCs were genetically modified to produce mutant β-galactosidase. Furthermore, a new nitric oxide prodrug, 6-methyl-galactose-benzyl-oxy NONOate, was designed.